Publications

2022

99. Chan, A.M., Goodis, C.C., Pommier, E.G. and Fletcher, S. “Recent applications of covalent chemistries in protein–protein interaction inhibitors.” RSC Med. Chem. 2022, 13, 921-928.

98. Drennen, B., Goodis, C.C., Bowen, N., Yu, W., Vickers, G., Wilder, P.T., MacKerell, Jr, A.D. and Fletcher, S. “Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.” RSC Med. Chem. 2022, 13, 963-969.

97. Zhang Y, Truong B, Fahl SP, Martinez E, Cai KQ, Al-Saleem ED, Gong Y, Liebermann DA, Soboloff J, Dunbrack R, Levine RL, Fletcher S, Kappes D, Sykes SM, Shapiro P and Wiest DL. “The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm.” Blood 2022, 140, 359-373.

96. Shukla S, Fletcher S, Chauhan J, Chalfant V, Riveros C, Mackeyev Y, Singh PK, Krishnan S, Osumi T and Balaji KC. “3JC48-3 (methyl 4′-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1′-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth.” Cancer Gene Ther. 2022, doi: 10.1038/s41417-022-00455-4.

2021

95. Martinez R 3rd, Huang W, Samadani R, Mackowiak B, Centola G, Chen L, Conlon IL, Hom K, Kane MA, Fletcher S and Shapiro P. “Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.” J. Pharmacol. Exp. Ther. 2021, 376, 84-97.

94. Fontana F, Scott MJ, Allen JS, Yang X, Cui G, Pan D, Yanaba N, Fiala MA, O’Neal J, Schmieder-Atteberry AH, Ritchey J, Rettig M, Simons K, Fletcher S, Vij R, DiPersio JF and Lanza GM. “VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.” Clin. Cancer Res. 2021, 27, 1974-1986.

93. Zheleznyak A, Mixdorf M, Marsala L, Prior J, Yang X, Cui G, Xu B, Fletcher S, Fontana F, Lanza G and Achilefu S. “Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.” Theranostics 2021, 11, 7735-7754.

92. Kaneshita S, Kida T, Yoshioka M, Nishioka K, Raje M, Sakashita A, Hirano A, Sagawa T, Kasahara A, Inoue T, Fujioka K, Nagahara H, Wada M, Kohno M, Strovel JW, Fletcher S, Ashihara E and Kawahito Y. “CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis.” Pulm. Pharmacol. Ther. 2021, 70, 102057.

2020

91. Conlon IL, Drennen B, Lanning ME, Hughes S, Rothhaas R, Wilder PT, MacKerell AD Jr, Fletcher S. “Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2.” ChemMedChem 2020, 15, 1691-1698.

90. Esser AK, Ross MH, Fontana F, Su X, Gabay A, Fox GC, Xu Y, Xiang J, Schmieder AH, Yang X, Cui G, Scott M, Achilefu S, Chauhan J, Fletcher S, Lanza GM and Weilbaecher KN. “Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.” Theranostics 2020, 10, 7510-7526.

89. Chan, A. M. and Fletcher, S. “Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.” RSC Med. Chem. 2020 12, 178-196.

88. Chauhan J, Yu W, Cardinale S, Opperman TJ, MacKerell AD Jr, Fletcher S and de Leeuw EP. “Optimization of a benzothiazole indolene scaffold targeting bacterial cell wall assembly.” Drug Des. Devel. Ther. 2020, 14, 567-574.

2019

87. Fletcher, S. “Mcl-1 inhibitors – Where are we now?” Expert Opin. Ther. Pat. 2019, 29, 909-911.

86. Conlon, I. L., Konsein, K., Morel, Y., Chan, A. and Fletcher, S. “Construction of 1H-indazoles from ortho-aminobenzoximes by the Mitsunobu reaction.” Tetrahedron Lett. 2019, 60, 150929.

85. Kazi, A., Xiang, S., Yang, H., Chen, L., Kennedy, P., Ayaz, M., Fletcher, S., Cummings, C., Lawrence, H., Beato, F., Yang, Y., Kim, M. P., Delitto, A., Underwood, P., Fleming, J. B., Trevino, J., Hamilton, A. D. and Sebti, S. M. “Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors.” Clin. Cancer Res. 2019, 25, 5984-5996.

84. Chauhan, J., Kwasny, S. M. and Fletcher, S., Opperman, T. J. and de Leeuw, E. P. H. “Optimization of a small-molecule Lipid II binder.” Bioorg. Med. Chem. Lett. 2019, 29, 1849-1853.

2018

83. Yang, S. M., Urban, D. J., Yoshioka, M., Strovel, J. W., Fletcher, S., Wang, A. Q., Xu, X., Shah, P., Hu, X., Hall, M. D., Jadhav, A. and Maloney, D. J. “Discovery and lead identification of quinazoline-based BRD4 inhibitors” Bioorg. Med. Chem. Lett. 2018, 28, 3483-3488.
82. Conlon, I. L., Van Eker, D., Abdelmalak, S., Murphy, W. A., Bashir, H., Sun, M., Chauhan, J., Varney, K. M., Godoy-Ruiz, R., Wilder, P. T. and Fletcher, S. “Kröhnke pyridines: Rapid and facile access to Mcl-1 inhibitors.” Bioorg. Med. Chem. Lett. 2018, 28, 1949-1953
81. Perri, M., Yap, J. L., Fletcher, S., Cione, E. and Kane, M. A. “Therapeutic potential of Bcl-xl/Mcl-1 synthetic inhibitor JY-1-106 and retinoids for human triple-negative breast cancer treatment.” Oncol. Lett. 2018, 15, 7231-7236.
80. Whiting, E., Raje, M. R., Chauhan, J., Wilder, P. T., Van Eker, D., Hughes, S. J., Bowen, N. G., Vickers, G. E. A., Fenimore, I. C. and Fletcher, S. “Discovery of Mcl-1 inhibitors based on a thiazolidine-2, 4-dione scaffold.” Bioorg. Med. Chem. Lett. 2018, 28, 523-528.

2017

79. Imayoshi, N., Yoshioka, M., Chauhan, J., Nakata, S., Toda, Y., Fletcher, S., Stovel, J. W., Takata, K. and Ashihara, E. “CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model.” Biochem. Biophys. Res. Commun. 2017, In press.

78. Carter-Cooper, B. A., Fletcher, S., Ferraris, D., Choi, E. Y., Kronfli, D., Dash, S., Truong, P., Sausville, E. A., Lapidus, R. G., Emadi, A. “Synthesis, Characterization and Antineoplastic Activity of Bis-Aziridinyl Dimeric Naphthoquinone – A Novel class of Compounds with Potent Activity against Acute Myeloid Leukemia Cells.” Bioorg. Med. Chem. Lett. 2017, 1, 6-10.

77. Chen, L. and Fletcher, S. “Mcl-1 Inhibitors: A Patent Review.” Expert Opin. Ther. Pat. 2017, 27, 163-178.

76. Yap, J. L., Chen, L., Lanning, M. E. and Fletcher, S. “Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Anti-Apoptotic Bcl-2 Proteins by Small-Molecules.” J. Med. Chem. 2017, In press.

2016

75. Van Eker, D., Chauhan, J., Murphy, W. A., Conlon, I. L. and Fletcher, S. “Chromatography-Free, Mitsunobu-Triggered Heterocyclizations of Salicylhydroxamic Acids to 3-Hydroxybenzisoxazoles.” Tetrahedron Lett. 2016, 57, 5301-5303.

74. Chauhan, J., MacKerell, A. D., Jr., Fletcher, S. and De Leeuw, E. “Towards Development of Small Molecule Lipid II inhibitors as Novel Antibiotics.” PLoS ONE 2016, 11(10): e0164515.

73. Lanning, M. E., Yu, W., Yap, J. L., Chauhan, J., Chen, L., Whiting, E., Pidugu, L. S., Atkinson, T., Bailey, H., Li, W., Roth, B. M., Hynicka, L., Chesko, K., Toth, E. A., Shapiro, P., MacKerell, A. D., Jr., Wilder, P. T. and Fletcher, S. “Structure-Based Design of N-Substituted 1-Hydroxy-4-sulfamoyl-2-naphthoates as Selective Inhibitors of the Mcl-1 Oncoprotein.” Eur. J. Med. Chem. 2016, 113, 273-292.

72. Drennen, B., Scheenstra, J. A., Yap, J. L., Chen, L., Lanning, M. E., Roth, B. M., Wilder, P. T. and Fletcher, S. “Structural Re-engineering of the α-Helix Mimetic JY-1-106 into Small Molecules: Disruption of the Mcl-1–Bak-BH3 Protein–Protein Interaction with 2,6-Di-Substituted Nicotinates.” ChemMedChem 2016, 11, 827-833.

71. Chen, L., Wilder, P. T., Drennen, B., Tran, J., Roth, B. M., Chesko, K., Shapiro, P. and Fletcher, S. “Structure-Based Design of 3-Carboxy-Substituted 1,2,3,4-Tetrahydroquinolines as Inhibitors of Myeloid Cell Leukemia-1 (Mcl-1).” Org. Biomol. Chem. 2016, 14, 5505-5510.

2015

70. Drennen, B., MacKerell, A. D., Jr. and Fletcher, S. “Expedient Access to Pre-Organized α-Helix Mimetics Based on an Isocinchomeronic Acid Core.” Tetrahedron Lett. 2015, 56, 6819-6822.

69. Chauhan, J., Chen, S.-E., Fenstermacher, K., Raje, M., DeStefano, J. J., Freire, E. and Fletcher, S. “Synthetic, Structural Mimetics of the ß-Hairpin Flap of HIV-1 Protease Inhibit Enzyme Function.” Bioorg. Med. Chem. 2015, 23, 7095-7109.

68. Lanning, M. E. and Fletcher, S. “Multi-Facial, Non-Peptidic α-Helix Mimetics.” Biology 2015, 4, 540-555.

67. Lanning, M. E., Wilder, P. T., Bailey, H., Drennen, B., Cavalier, M., Chen, L., Yap, J. L., Raje, M. and Fletcher, S. “Towards More Drug-Like Proteomimetics: Two-Faced, Synthetic α-Helix Mimetics Based on a Purine Scaffold.” Org. Biomol. Chem. 2015, 13, 8642-8646.

66. Chen, L., Yap, J. L., Yoshioka, M., Lanning, M. E., Fountain, R. N., Scheenstra, J. A., Raje, M., Strovel, J. W. and Fletcher, S. “BRD4 Structure–Activity Relationships of Dual PLK1 Kinase-BRD4 Bromodomain Inhibitor BI-2536.” ACS Med. Chem. Lett. 2015, 6, 764-769.

65. Wang, H., Fletcher, S., Ramakrishnan, A. and Prochownik, E. V. “A Quantitative, Surface Plasmon Resonance-Based Approach to Evaluating DNA Binding by the c-Myc Oncoprotein and its Disruption by Small Molecule Inhibitors” J. Biol. Methods 2015, 2, e18.

64. Wang, H., Sharma, L., Lu, J., Finch, P., Fletcher, S. and Prochownik, E.V. “Structurally Diverse c-Myc Inhibitors Share a Common Mechanism of Action Involving ATP Depletion.” Oncotarget 2015, 6, 15857-15870.

63. Mistry, P. Chauhan, J., Fletcher, S., MacKerell, Jr., A. D. and Vogel, S. N. “Inhibition of TLR2 Signaling by Novel Small Molecule Inhibitors Targeting a Pocket within the TLR2 TIR Domain” Proc. Natl. Acad. Sci. 2015, 112, 5455-5560.

62. Zhang, J., Samadani, R., Oashi, T., Jung, K.-Y., Fletcher, S., MacKerell, Jr., A. D. and Shapiro, P. “Identification of Small Molecule Inhibitors of ERK1/2-regulated AP-1 Proteins that Selectively Inhibit Melanoma Cells Expressing Mutated BRaf.” Biochem. J. 2015, 467, 425-438.

61. Jung, K.-Y., Wang, H., Yap, J. L., Chen, L., Lanning, M. E., Prochownik, E. V. and Fletcher, S. “Disruption of the c-Myc–Max Protein–Protein Interaction via a Synthetic α-Helix Mimetic Strategy.” J. Med. Chem. 2015, 58, 3002-3024.

60. Fletcher, S. “The Mitsunobu Reaction in the 21st Century.” Org. Chem. Front. 2015, 2, 739-752.

59. Whiting, E., Lanning, M. E., Scheenstra, J. A. and Fletcher, S. “Chromatography-Free Entry to Substituted Salicylonitriles: Mitsunobu-Triggered, Domino Reactions of Salicylaldoximes.” J. Org. Chem. 2015, 80, 1229–1234.57.

58. Fletcher, S., Yu, W., MacKerell, Jr. A. D. and de Leeuw, E. “Structure–Activity Relationships of a Small-Molecule Lipid II Inhibitor.” Drug Des. Dev. Ther. 2015, 9, 2383-2394.

2014

57. Chen, L., Lanning, M. E. and Fletcher, S. “Small-Molecule Inhibitors of the Mcl-1 Oncoprotein.” Austin J. Anal Pharm. Chem. 2014, 1:1015.

56. Perri, M., Yu, J., Yap, J. L., Fletcher, S. and Kane, M. A. “Bcl-xL/Mcl-1 Inhibition and RARg Antagonism Work Cooperatively in Human HL60 Leukemia Cells.” Exp. Cell. Res. 2014, 327, 183-191.

55. Chauhan, J., Wang, H., Yap, J. L., Sabato, P. E., Hu, A., Prochownik, E. V. and Fletcher, S. “Discovery of Methyl 4′-Methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1′-biphenyl]-3-carboxylate, an Improved Small-Molecule Inhibitor of c-Myc–Max Dimerization.” ChemMedChem 2014, 9, 2274-2285.

54. Chen, L. and Fletcher, S. “O-Alkylation of 3-Hydroxyisoxazoles Predominates under Mitsunobu Conditions.” Tetrahedron Lett. 2014, 55, 1693–1696.

53. Fletcher, S. and Prochownik, E. V. “Small-Molecule Inhibitors of the Myc Oncoprotein.” Biochim. Biophys. Acta. 2014, doi: 10.1016/j.bbagrm.2014.03.005.

52. Kao, J. P. Y., Muralidharan, S., Fletcher, S., Xue, F. and Rosen, G. M. “Baeyer-Villiger Rearrangement of a Substituted Pyrrole by Oxone.” Tetrahedron Lett. 2014, 55, 3111–3113.

2013

51. Lanning, M. E. and Fletcher, S. “Recapitulating the Alpha-Helix: Non-Peptidic Low-Molecular-Weight Ligands for the Manipulation of Protein–Protein Interactions.” Future Med. Chem. 2013, 5, 2157–2174.

50. Lanning, M. E. and Fletcher, S. “Azodicarbonyl dimorpholide (ADDM): An efficient, versatile and water-soluble Mitsunobu reagent.” Tetrahedron Lett. 2013, 54, 4624-4628.

49. Wang, H., Chauhan, J., Hu, A., Yap, J. L., Sabato, P. E., Jones, J. W., Perri, M., Yu, J., Cione, E., Kane, M. A., Fletcher, S. and Prochownik, E. V. “Improved Uptake and Efficacy of Novel Analogs of the Myc Inhibitor 10074-G5.” Oncotarget 2013, 4:936–947.

48. Jung, K.-Y., Vanommeslaeghe, K., Lanning, M. E., Yap, J. L., Gordon, C., MacKerell, Jr., A. D. and Fletcher, S. “Amphipathic Alpha-Helix Mimetics Based on a 1,2-Diphenylacetylene Scaffold.” Org. Lett. 2013, 15, 3234–3237.

47. Cao, X., Yap, J. L., Newell-Rogers, M. K., Peddaboina, C., Hua, J., Papaconstantinou, H. T., Jupitor, D., Rai, A., Jung, K.-Y.,Tubin, R. P., Yu, W., Vanommeslaeghe, K., Wilder, P. T., MacKerell, Jr., A. D., Fletcher, S. and Smythe, W. R. “The Novel BH3 Alpha-Helix Mimetic JY-1-106 Induces Apoptosis in a Subset of Cancer Cells (Lung Cancer, Colon Cancer and Mesothelioma) by Disrupting Bcl-xL and Mcl-1 Protein–Protein Interactions with Bak.” Mol. Cancer 2013, 12:42.

46. Rosen, G. M., Muralidharan, S., Zavalij, P. Y., Fletcher, S. and Kao, J. P. Y. “2,5-Di(tert-Butyl)-5-ethoxy-4-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate.” Acta Crystallogr. Sect. E. 2013, E69, o878.

45. Jung, K.-Y., Samadani, R., Chauhan, J., Nevels, K., Yap, J. L., Zhang, J., Worlikar, S., Lanning, M. E., Chen, L., Ensey, M., Shukla, S., Salmo, R., Heinzl, G., Gordon, C., Dukes, T., MacKerell, Jr., A. D., Shapiro, P. and Fletcher, S. “Structural Modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that Improve Selectivity for the Inhibition of Melanoma Cells Containing Active ERK Signaling.” Org. Biomol. Chem. 2013, 11, 3706–3732.

44. Haftchenary, S., Ball, D. P., Aubry, I., Landry, M., Shahani, V. M., Fletcher, S., Page, B. D. G., Jouk, A. O., Tremblay, M. L. and Gunning, P. T. “Identification of a Potent, Salicylic Acid-Based Inhibitor of Phosphatase PTP1B.” Med. Chem. Commun. 2013, 4, 987–992.

43. Levi, R., Fornero, S., Heymans, S., Fletcher, S., Page, B. D. G., Gunning, P. T. and Camporeale, A. “Systemic Constitutively Active STAT3 Triggers the Onset of Immune-Mediated Myocarditis: Implications for the Development of Severe Disease upon Heart Inflammation.” EEMBO Mol. Med. 2013, 5, 572–590.

42. Yap, J. L., Wang, H., Hu, A., Chauhan, J., Jung, K.-Y., Gharavi, R. B., Prochwonik, E. V. and Fletcher, S. “Pharmacophore Indentification of c-Myc Inhibitor 10074-G5.” Bioorg. Med. Chem. Lett. 2013, 230, 370–374.

2012

41. Peddaboina, C., Jupiter, D., Fletcher, S., Yap, J. L., Rai, A., Tobin, R. Jiang, W., Rascoe, P., Rogers, M. K., Smythe, W. R. and Cao, X. “The Downregulation of Mcl-1 via USP9X inhibition Sensitizes Solid Tumors to Bcl-xL Inhibition.” BMC Cancer 2012, 12:541.

40. Jung, K.-Y. and Fletcher, S. “Fine-tuning the Chemo- and Regioselective Alkylation of 1,4-Benzodiazepines: Further Applications of the Mitsunobu Reaction.” Med. Chem. Commun. 2012, 3, 1160–1163.

39. Chauhan, J. and Fletcher, S. “One-pot Synthesis of 2,1-Benzisoxazoles (Anthranils) by a Stannous Chloride-Mediated Tandem Reduction–Heterocyclization of 2-Nitroacylbenzenes under Neutral Conditions.” Tetrahedron Lett. 2012, 53, 4951–4954.

38. Yap, J. L., Cao, X., Vanommeslaeghe, K., Jung, K.-Y., Wilder, P., Nan, A., MacKerell, A. D., Jr., Smythe, W. R. and Fletcher, S. “Relaxation of the Rigid Backbone of an Oligoamide-Foldamer-Based a-Helix Mimetic: Identification of Potent Bcl-xL Inhibitors.” Org. Biomol. Chem. 2012, 10, 2928–2933.

37. Yap, J. L., Chauhan, J., Jung, K.-Y., Chen, L., Prochownik, E. V. and Fletcher, S. “Small-Molecule Inhibitors of Dimeric Transcription Factors: Antagonism of Protein–Protein and Protein–DNA Interactions.” Med. Chem. Commun. 2012, 3, 541–551.

36. Page, B. D. G., Khoury, H., Laister, R. C., Fletcher, S., Vellozo, M., Manzoli, A., Yue, P., Turkson, J., Minden, M. D. and Gunning, P. T. “Small-Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity.” J. Med. Chem. 2012, 55, 1047–1055.

35. Mitra, R. N., Doshi, M., Zhang, X., Tyus, J. C., Bengtsson, N., Fletcher, S., Page, B. D. G., Turkson, J., Gesquiere, A. J., Gunning, P. T., Walter, G. A., Santra, S. “An Activatable Multimodal/Multifunctional Nanoprobe for Direct Imaging of Intracellular Drug Delivery.” Biomaterials 2012, 33, 1500–1508.

2011

34. Fletcher, S., Avadisian, M.; Liu, B., Zhao, W., Yue, P., Badali, D., Xu, W., Schimmer, A. D., Turkson, J., Gradinaru, C. C. and Gunning, P. T. “Artificially Induced Protein–Membrane Anchorage with Cholesterol-Based Recognition Agents as a New Therapeutic Concept.” Angewandte Chemie, Int. Ed. 2011, 50, 6248–6253.

33. Page, B. D. G., Fletcher, S., Yue, P., Li, Z., Zhang, X., Sharmeen, S., Datti, A., Wrana, J. L., Trudel, S., Schimmer, A. D., Turkson, J. and Gunning, P. T. “Identification of a Non-phosphorylated, Cell Permeable, Small Molecule Ligand for the Stat3 SH2 Domain.” Bioorg. Med. Chem. Lett. 2011, 21, 5605–5609.

32. Yap, J. L., Hom, K. and Fletcher, S. “Ortho-Selectivity in the Nucleophilic Aromatic Substitution (SNAr) Reactions of 3-Substituted, 2,6-Dichloropyridines by Alkali Metal Alkoxides.” Tetrahedron Lett. 2011, 52, 4172–4176.

31. Fletcher, S., Page, B. D. G., Zhang, X., Turkson, J. and Gunning, P. T. “Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules.” ChemMedChem 2011, 6, 1459–1470.

30. Shahani, V., Yue, P., Fletcher, S., Sharmeen, S., Sukhai, M., Luu, D., Zhang, X., Sun, H., Zhao, W., Schimmer, A. D., Turkson, J. and Gunning, P. T. “Design, Synthesis and in vitro Characterization of Novel Hybrid Peptidomimetic Inhibitors of Stat3 Protein.” Bioorg. Med. Chem. 2011, 19, 1823–1838.

29. Rais, R., Fletcher, S. and Polli, J. “Synthesis and in vitro Evaluation of Gabapentin Prodrugs that Target the Human Apical Sodium Dependent Bile Acid Transporter (hASBT).” J. Pharm. Sci. 2011, 100, 1184–1195.

28. Yap, J. L., Worlikar, S. MacKerell, A. D., Jr., Shapiro, P. and Fletcher S. “Small Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics.” ChemMedChem 2011, 6, 38–48.

2010

27. Fletcher, S., Pusateri, E. E., Cummings, C. G., Blaskovich, M. A., Hast, M. A., Glenn, M. P., Chang, S.-Y., Buchner, C. J., Floyd, R. J., Katt, W. P., Beese, L. S., Sebti, S. M. and Hamilton, A. D. “Structure-Based Design and Synthesis of Potent, Anticancer, Mammalian Farnesyltransferase Inhibitors Based on an Ethylenediamine Scaffold.” J. Med. Chem. 2010, 53, 6867 – 6888.

26. Fletcher, S. “Regioselective Alkylation of the Exocyclic Nitrogen of Adenine and Adenosine by an Efficient Mitsunobu Reaction.” Tetrahedron Lett. 2010, 51, 2948–2950.

25. Fletcher, S. and Gunning, P. T. “Concise Access to N9-Mono, N2-Mono and N2,N9-Di-Substituted Guanines via Efficient Mitsunobu Reactions.” Tetrahedron 2010, 66, 4621–4632.

24. Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T. and Turkson, J. “A Novel Small-Molecule Disrupts Stat3 SH2 Domain–Phosphotyrosine Interactions and Stat3-Dependent Tumor Processes.” Biochem. Pharmacol. 2010, 79, 1398–1409.

23. Drewry, J., Fletcher, S., Xiou, P., Turkson, J. and Gunning, P. T. “Co-ordination Complex SH2 Domain Proteomimetics: An Alternative Approach to Disrupting Oncogenic Protein–Protein Interactions.” ChemCommun. 2010, 46, 892–894.

2009

22. Drewry, J., Fletcher, S., Hassan. H. and Gunning, P. T. “Novel Asymmetrically Functionalized BDPA Metal Complexes: Peripheral Decoration of a Potent Anion Recognition Scaffold.” Org. Biomol. Chem. 2009, 7, 5074–5077.

21. Marguiles, D., Opatowsky, Y., Fletcher, S., Saraogi, I., Tsou, K., Saha, S., Schlessinger, J. and Hamilton, A. D. “Surface Binding Inhibitors of SCF-Kit Protein–Protein Interactions.” ChemBioChem 2009, 10, 1955–1958.

20. Fletcher, S., Zhang, X., Singh, J., Turkson, J. and Gunning, P. T. “Disruption of Transcriptionally Active Stat3 Dimers with Non-Phosphorylated, Salicylic Acid-Based Small Molecules: Potent in vitro and Tumour Cell Activities.” ChemBioChem 2009, 10, 1959–1964.

19. Fletcher, S., Drewry, J., Shahani, V., Page, B. and Gunning, P. T. “Molecular Disruption of Signal Transducer and Activator of Transcription 3 (Stat3) Oncogenic Activity.” Biochem. Cell Biol. 2009, 87, 825–833.

18. Liu, B., Fletcher, S., Avadisian, M., Gunning, P. T. and Gradinaru, C. “A Photostable, pH-Invariant Fluorescein Derivative for Single-Molecule Microscopy.” J. Fluoresc. 2009, 19, 915–920.

17. Fletcher, S., Shahani, V. and Gunning, P. T. “Facile and Efficient Access to 2,6,9-Tri-Substituted Purines through Sequential N9, N2 Mitsunobu Reactions.” Tetrahedron Lett. 2009, 50, 4258–4261.

16. Hast, M. A., Fletcher, S., Cummings, C. G., Pusateri, E. E., Blaskovich, M. A., Rivas, K., Gelb, M. H., Van Voorhis, W. C., Hamilton, A. D. and Beese, L. S. “Structural Basis for Binding and Selectivity of Antimalarial and Anticancer Ethylenediamine Inhibitors to Protein Farnesyltransferase.” Chem. Biol. 2009, 16, 181–192.

2008

15. Fletcher, S. and Gunning, P. T. “Mild, Efficient and Rapid Debenzylation of ortho-Substituted Phenols with Trifluoroacetic Acid.” Tetrahedron Lett. 2008, 49, 4817–4819.

14. Fletcher, S., Turkson, J. and Gunning, P. T. “Molecular Approaches Towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein.” ChemMedChem 2008, 3, 1159–1168.

13. Fletcher, S., Cummings, C. G., Rivas, K., Katt, W. P., Horney, C., Buckner, F. S., Chakrabarti, D., Sebti, S. M., Gelb, M. H., Van Voorhis, W. C. and Hamilton, A. D. “Potent, Plasmodium-Selective Farnesyltransferase Inhibitors that Arrest the Growth of Malaria Parasites: Structure–Activity Relationship Studies of Ethylenediamine-Analogue Scaffolds and Homology Model Validation.” J. Med. Chem. 2008, 51, 5176–5197.

12. Fletcher, S., Ahmad, A., Price, W. S., Jorgensen, M. R. and Miller, A. D. “Biophysical Properties of CDAN/DOPE-Analogue Lipoplexes Account for Enhanced Gene Delivery.” ChemBioChem 2008, 9, 455–463.

2007

11. Fletcher, S. and Hamilton, A. D. “Denaturation and Accelerated Proteolysis of Sizeable Heme Proteins by Synthetic Metalloporphyrins.” New J. Chem. 2007, 31, 632–627.

10. Fletcher, S. and Hamilton, A. D. “Protein–Protein Interaction Inhibitors: Small Molecules from Screening Techniques.” Curr. Top. Med. Chem. 2007, 7, 922–927.

9. Wilson, A., Hong, J., Fletcher, S. and Hamilton, A. D. “Recognition of Solvent Exposed Protein Surfaces using Anthracene Derived Receptors.” Org. Biomol. Chem. 2007, 5, 276–285.

8. Tagore, D. M., Sprinz, K. I., Fletcher, S., Jayawickramarajah, J. and Hamilton, A. D. “Protein Recognition and Denaturation by Self-Assembling Fragments on a DNA Quadruplex Scaffold.” Angew. Chem., Int. Ed. 2007, 46, 223–225.

2006

7. Price, W. S., Fletcher, S., Jorgensen, M. R. and Miller, A. D. “A Novel Methodology for the Synthesis of Fumarates and Maleates.” Synlett 2006, 12, 1933–1937.

6. Glenn, M. P., Chang, S.-Y., Horney, C., Rivas, K., Yokoyama, K., Pusateri, E. E., Fletcher, S., Cummings, C. G., Buckner, F. S., Pendyala, P. R., Chakrabarti, D., Sebti, S. M., Gelb, M. H., Van Voorhis, W. C. and Hamilton, A. D. “Structurally Simple, Potent, Plasmodium-Selective Farnesyltransferase Inhibitors that Arrest the Growth of Malaria Parasites.” J. Med. Chem. 2006, 49, 5710–5727.

5. Fletcher, S. and Hamilton, A. D. “Targeting Protein–Protein Interactions by Rational Design: Mimicry of Protein Surfaces.” J. R. Soc. Interface 2006, 3, 215–233.

4. Fletcher, S., Ahmad, A., Perouzel, E., Jorgensen, M. R. and Miller, A. D. “A Dialkynoyl Analogue of DOPE Improves Gene Transfer of Lower-Charged, Cationic Lipoplexes.” Org. Biomol. Chem. 2006, 4, 196–199.  Our article was featured on the front cover of Issue 2, 2006.

3. Fletcher, S., Ahmad, A., Perouzel, E., Heron, A., Miller, A. D. and Jorgensen, M. R. “In Vivo Studies of Dialkynoyl Analogues of DOTAP Demonstrate Improved Gene Transfer Efficiency in Mouse Lung.” J. Med. Chem. 2006, 49, 349–357.

2005

2. Fletcher, S. and Hamilton, A. D. “Protein Surface Recognition and Proteomimetics: Mimics of Protein Surface Structure and Function.” Curr. Opin. Chem. Biol. 2005, 9, 632–638.

2004

1. Fletcher, S., Jorgensen, M. R. and Miller, A. D. “A Facile Preparation of an Orthogonally-Protected, pH-Sensitive, Bioconjugate Linker for Therapeutic Applications.” Org. Lett. 2004, 6, 4245–4248.